Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Arena Pharmaceuticals ( ARNA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.8%. By the end of trading, Arena Pharmaceuticals rose 61 cents (6%) to $10.81 on heavy volume. Throughout the day, 27.9 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 8.6 million shares. The stock ranged in a price between $10.13-$10.95 after having opened the day at $10.34 as compared to the previous trading day's close of $10.20. Other companies within the Drugs industry that increased today were: Bioline Rx ( BLRX), up 14.7%, Galectin Therapeutics ( GALT), up 14.5%, Aoxing Pharmaceutical Company ( AXN), up 13.6%, and Cormedix ( CRMD), up 11.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.1 billion and is part of the health care sector. Shares are up 7.1% year to date as of the close of trading on Monday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and five rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its meager revenue growth.

On the negative front, China Botanic Pharmaceutical ( CBP), down 12.7%, Telik ( TELK), down 11.6%, Biocryst Pharmaceuticals ( BCRX), down 9%, and Zalicus ( ZLCS), down 7.1%, were all laggards within the drugs industry with Amgen ( AMGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade.

null

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit